ACP3 and neoplasm: Peptide PSCA14–22, ALQPGTALL, was able to generate a T cell response specific to PSCAin a human lymphocyte culture from a patient with metastatic prostatecancer.126 Peptides (nonamers) from prostaticacid phosphatase (PAP), a prostate tissue-specific antigen that bindsHLA-A*02, were identified.125 The leadpeptide ALDVYNGLL was used to generate tumor-specific CTLs in a studyof PAP-based antigens for immunotherapy in prostate cancer.125